Neurosphere involved in a new project with Neurasic Therapeutics, CQDM and Louise and Alan Edwards Foundation
NeuroSphere is pleased to continue to support Neurasic Therapeutics and Dr. Philippe S茅gu茅la since our involvement in the launch of Neurasic therapeutics in 2020聽and announce a聽new聽$965,000 collaboration between聽Neurasic Therapeutics, CQDM, the Louise and Alan Edwards Foundation, and Neurosphere. This collaborative research project has聽the potential to make progress towards the development of a new class of analgesics designed to combat refractory pain without the side effects of opioids.聽
This new project is lead by聽Philippe S茅gu茅la,聽a pioneer in the identification of pain channel genes and non-opioid analgesic mechanisms, at the Neuro (Montreal Neurological Institute-Hospital). The project聽is made possible through CQDM innovation funding and a contribution of $200,000 from HBHL.
聽鈥淭hrough its Neuro-Partnerships Program, HBHL is proud to help fund this new project in collaboration with CQDM and other industry partners," said聽Xavier Linker, Associate Director of Business Development at HBHL.聽"As this project aims to provide new opiate-sparing pain-relieving drugs, it aligns perfectly with HBHL鈥檚 vision to improve the quality of life of Canadians and people around the world. Furthermore, funding this project builds on the previous work done by NeuroSphere, 平特五不中鈥檚 neuroscience accelerator funded through HBHL, to help start Neurasic Therapeutics.鈥�
